Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Humana Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.65, while Humana Inc trades at $393.72 (market cap $48.96B). The key difference: Humana Inc pays a 0.87% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Humana Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | HUM | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $409.42 |
52-Week Low | $91.59 | $163.67 |
Market Cap | — | $48.96B |
Enterprise Value | — | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
Humana (HUM) trades at $395.78, down 2.68% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $10.31, beating expectations, and maintains a P/E of 43.52 and P/S of 0.36. Recent news highlights margin recovery targets and expansion through CenterWell, while investigations into insider sales and cost statements introduce uncertainty.
Outlook is mixed: analyst consensus is $354.33 with 61% hold ratings, reflecting caution despite growth initiatives. Key risks include Medicare Advantage margin pressures and legal scrutiny, but revenue growth to $137.2B in 2026 and a dividend payment in July offer support. Investors should weigh profitability trends against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
